Chandra Bhagat Pharma Ltd Stock Price Today (NSE: CBPL)
Fundamental Score
Chandra Bhagat Pharma Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Chandra Bhagat Pharma Ltd share price today is ₹43.50, up +0.00% on NSE/BSE as of 19 June 2026. Chandra Bhagat Pharma Ltd (CBPL) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹29.20 (Cr). The 52-week high for CBPL share price is ₹59.00 and the 52-week low is ₹29.70. At a P/E ratio of 47.10x, CBPL is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 2.41% and a debt-to-equity ratio of 0.69.
Chandra Bhagat Pharma Ltd Share Price Chart — NSE/BSE Historical Performance
Chandra Bhagat Pharma Ltd share price chart: 33.33% return over the past month. 52-week high ₹59.00, 52-week low ₹29.70.
Chandra Bhagat Pharma Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹46.20 | ₹46.20 | ₹43.50 | ₹43.50 | 24.00K (Cr) | |
| ₹46.20 | ₹46.20 | ₹42.51 | ₹44.00 | 6.00K (Cr) | |
| ₹40.00 | ₹40.00 | ₹40.00 | ₹40.00 | 0.00 (Cr) | |
| ₹40.00 | ₹40.00 | ₹40.00 | ₹40.00 | 0.00 (Cr) | |
| ₹44.00 | ₹44.00 | ₹44.00 | ₹44.00 | 10.00K (Cr) | |
| ₹38.00 | ₹41.80 | ₹38.00 | ₹40.00 | 34.00K (Cr) | |
| ₹36.30 | ₹39.93 | ₹36.30 | ₹38.00 | 68.00K (Cr) | |
| ₹36.30 | ₹36.30 | ₹36.30 | ₹36.30 | 3.00K (Cr) | |
| ₹32.00 | ₹33.00 | ₹32.00 | ₹33.00 | 10.00K (Cr) | |
| ₹31.09 | ₹31.60 | ₹29.70 | ₹31.60 | 12.00K (Cr) |
Chandra Bhagat Pharma Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹46.20 | ₹46.20 | ₹43.50 | ₹43.50 | -5.84% | |
| ₹31.09 | ₹46.20 | ₹29.70 | ₹44.00 | +41.52% | |
| ₹32.00 | ₹37.00 | ₹30.12 | ₹33.00 | +3.13% | |
| ₹39.50 | ₹39.50 | ₹29.95 | ₹30.50 | -22.78% | |
| ₹42.20 | ₹42.20 | ₹36.20 | ₹39.45 | -6.52% | |
| ₹39.90 | ₹42.10 | ₹39.19 | ₹42.10 | +5.51% | |
| ₹35.00 | ₹48.95 | ₹33.00 | ₹41.25 | +17.86% | |
| ₹38.00 | ₹40.01 | ₹38.00 | ₹38.70 | +1.84% | |
| ₹37.10 | ₹48.00 | ₹37.10 | ₹41.12 | +10.84% | |
| ₹55.00 | ₹55.00 | ₹43.00 | ₹43.00 | -21.82% | |
| ₹55.00 | ₹59.00 | ₹51.00 | ₹54.70 | -0.55% | |
| ₹58.00 | ₹59.00 | ₹48.39 | ₹57.00 | -1.72% |
AI Research Briefing
Powered by Gemini · 2026-04-10
CBPL is a micro-cap value trap with weak fundamentals and overvaluation.
WHAT'S HAPPENING NOW (last 2-4 weeks)
No major catalysts found after live search. The most recent news relates to routine disclosures.
CORE STORY (THE REAL GAME)
CBPL is not a growth story, but a micro-cap play on promoter holding increase and potential takeover speculation. It's a gamble on someone seeing value where the market currently doesn't.
- Promoter holding increase
- Micro-cap size
- Sector tailwinds
- Takeover offer
- Significant order win
- Turnaround in financials
- Micro/SME cap - liquidity risk
- High P/E ratio
- Weak financials
Promoter increased holding by 0.99%. FII and DII holdings are negligible.
Indian pharmaceutical industry is projected to grow, but CBPL is underperforming.
No - Free Cash Flow 5Y: ₹22.63 Cr, but latest quarter is weak.
Unless there's a significant turnaround in financials or a takeover offer, CBPL's outlook remains bleak. Expect continued underperformance.
Primary Thesis Risk
Reliance on hope rather than fundamentals.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Chandra Bhagat Pharma Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Chandra Bhagat Pharma Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of CBPL across key market metrics for learning purposes.
Positive Indicators
4 factors identified
Excellent EPS Growth (18.03% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (18.03% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Balanced Promoter Holding (72.19%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
10 factors identified
Below-Average Return on Equity (2.41%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (6.00%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Margin Pressure Concerns (0.24%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Premium Valuation Risk (P/E: 47.10x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Profit Decline Concern (-33.82%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Revenue Contraction (-60.64%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Limited Growth History (-1.59% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Interest Coverage (1.60x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Limited Institutional Interest (FII+DII: 0.61%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Chandra Bhagat Pharma Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Chandra Bhagat Pharma Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Chandra Bhagat Pharma LtdChandra Bhagat ...Selected✓ CBPL • 542934 | 26.3/100 | ₹43.50₹44 | ₹29.20₹29.20 | 47.10Average 47.1 Average | 2.41%Poor 2.41% Poor | 6.00%Poor 6.00% Poor | 0.69Good 0.7 Good | 18.03%Excellent 18.03% Excellent | -1.59%Poor -1.59% Poor | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1844.30₹1844 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4537.80₹4538 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1319.00₹1319 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2276.40₹2276 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2420.40₹2420 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Chandra Bhagat Pharma Ltd PE Ratio History
Historical price-to-earnings ratio for CBPL — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2024 | ₹2.03 | ₹65.67 | 32.3x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Chandra Bhagat Pharma Ltd Quarterly Performance
Latest quarterly metrics for CBPL — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
-60.64%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-33.82%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
-1.59%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
18.03%
Compounded annual net profit growth over 5 years
Chandra Bhagat Pharma Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for CBPL — calculated from daily price history
Momentum is strong — price may be stretched. Watch for pullbacks.
Technical indicators are for educational purposes only. Not investment advice.
Chandra Bhagat Pharma Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Chandra Bhagat Pharma Ltd (CBPL) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Chandra Bhagat Pharma Ltd
About CBPL (Chandra Bhagat Pharma Ltd)
Chandra Bhagat Pharma Ltd is a dynamic and rapidly expanding pharmaceutical company dedicated to providing high-quality healthcare solutions across a diverse range of therapeutic a...reas. With a steadfast commitment to innovation and patient well-being, CBPL focuses on the development, manufacturing, and commercialization of essential medicines that address unmet medical needs. Our portfolio encompasses a broad spectrum of formulations, from life-saving injectables to convenient oral dosages, ensuring accessibility and ease of administration for healthcare professionals and patients alike. We strive to deliver impactful therapies that improve outcomes and enhance the quality of life for individuals around the world, building a reputation for reliability, integrity, and excellence in the pharmaceutical industry. CBPL is deeply invested in forging strong partnerships with healthcare providers and institutions to ensure seamless delivery of our products and to stay abreast of evolving medical needs. We maintain a robust distribution network that enables us to efficiently reach hospitals, clinics, and pharmacies throughout India and select international markets. Our highly skilled and dedicated team of professionals is driven by a shared vision of making a positive difference in the lives of patients. We are committed to upholding the highest standards of quality and safety in all aspects of our operations, from sourcing raw materials to manufacturing processes and quality control measures. Our unwavering dedication to research and development is at the heart of our growth strategy. CBPL continuously explores opportunities to expand our product pipeline with novel therapies and innovative drug delivery systems. We believe in investing in cutting-edge technologies and fostering a culture of scientific excellence to drive advancements in healthcare. Through strategic collaborations and partnerships, we seek to leverage the expertise of leading researchers and institutions to accelerate the development of groundbreaking solutions that address the most pressing medical challenges of our time, ultimately contributing to a healthier future for all.
Company Details
Key Leadership
CBPL Share Price: Frequently Asked Questions
What is the current share price of Chandra Bhagat Pharma Ltd?
Chandra Bhagat Pharma Ltd (CBPL) trades at ₹43.50 on NSE and BSE. Market cap ₹29.20 (Cr). Educational data only.
What is the P/E ratio of Chandra Bhagat Pharma Ltd?
Chandra Bhagat Pharma Ltd has a P/E of 47.10x vs industry average 31.77x.
What is the Bull Run score for Chandra Bhagat Pharma Ltd?
Chandra Bhagat Pharma Ltd has a Bull Run score of 26.3/100 based on 25+ financial parameters.
Does Chandra Bhagat Pharma Ltd pay dividends?
Chandra Bhagat Pharma Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Chandra Bhagat Pharma Ltd?
Chandra Bhagat Pharma Ltd has ROE of 2.41%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Chandra Bhagat Pharma Ltd?
Chandra Bhagat Pharma Ltd has debt-to-equity of 0.69.
Is Chandra Bhagat Pharma Ltd a good investment?
Bull Run gives Chandra Bhagat Pharma Ltd a score of 26.3/100. This is not investment advice — consult a SEBI-registered advisor.